ContactsInvestor RelationsSpark Therapeutics, Inc.Stephen W. WebsterChief Financial Officer(855) SPARKTX (1-855-772-7589)MediaTen Bridge CommunicationsDan Quinn(781) email@example.comFinancial MediaTeneo StrategyAndy Maas(212) firstname.lastname@example.org
PHILADELPHIA, Oct. 28, 2015 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE) today announced that it will host a conference call on Wednesday, November 4, 2015 at 8:30 a.m. Eastern to report corporate and financial results for the three and nine months ended September 30, 2015. The call can be accessed by dialing (855) 851-4526 (domestic) or (720) 634-2901 (international), and entering passcode 69969566. To access a live audio webcast, please visit the "Investors" section at www.sparktx.com. A replay of the call will be available for one week following the call and can be accessed by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international), and entering passcode 69969566 or also available on our website. About Spark Therapeutics Spark is a gene therapy leader seeking to transform the lives of patients with debilitating genetic diseases by developing one-time, life-altering treatments. Spark's initial focus is on treating rare diseases where no, or only palliative, therapies exist. Spark's most advanced product candidate, SPK-RPE65, which has received both breakthrough therapy and orphan product designation, recently reported positive top-line results from a pivotal Phase 3 clinical trial for the treatment of rare blinding conditions. Spark's validated gene therapy platform is being applied to a range of clinical and preclinical programs addressing serious genetic diseases, including inherited retinal dystrophies, hematologic disorders and neurodegenerative diseases. Spark builds on two decades of research, development and manufacturing at The Children's Hospital of Philadelphia, including human trials conducted across diverse therapeutic areas and routes of administration. To learn more, please visit www.sparktx.com.